JPH07504677A - 食餌用ホエータンパク質を用いたhiv‐血清陽性患者の治療法 - Google Patents
食餌用ホエータンパク質を用いたhiv‐血清陽性患者の治療法Info
- Publication number
- JPH07504677A JPH07504677A JP5517869A JP51786993A JPH07504677A JP H07504677 A JPH07504677 A JP H07504677A JP 5517869 A JP5517869 A JP 5517869A JP 51786993 A JP51786993 A JP 51786993A JP H07504677 A JPH07504677 A JP H07504677A
- Authority
- JP
- Japan
- Prior art keywords
- whey protein
- hiv
- protein concentrate
- seropositive
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 45
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 41
- 235000021119 whey protein Nutrition 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims description 10
- 235000005911 diet Nutrition 0.000 title description 16
- 230000000378 dietary effect Effects 0.000 title description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 83
- 229960003180 glutathione Drugs 0.000 claims abstract description 41
- 108010024636 Glutathione Proteins 0.000 claims abstract description 36
- 239000012141 concentrate Substances 0.000 claims abstract description 33
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 7
- 230000037396 body weight Effects 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 17
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 102000007562 Serum Albumin Human genes 0.000 claims description 13
- 108010071390 Serum Albumin Proteins 0.000 claims description 13
- 229940072221 immunoglobulins Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 4
- 102000008192 Lactoglobulins Human genes 0.000 claims description 3
- 108010060630 Lactoglobulins Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000004407 Lactalbumin Human genes 0.000 claims 1
- 108090000942 Lactalbumin Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 235000021241 α-lactalbumin Nutrition 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940099472 immunoglobulin a Drugs 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014103 egg white Nutrition 0.000 description 3
- 210000000969 egg white Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 108700006766 Glutathione synthetase deficiency Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 208000025657 inherited glutathione synthetase deficiency Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- -1 sulfosalicyl Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AFRDPBJNFFSFJD-SWOGJVQHSA-N (2r,7s)-2,7-diamino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]-4-oxooctanedioic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)C([C@H](N)C(O)=O)SSC[C@H](N)C(O)=O AFRDPBJNFFSFJD-SWOGJVQHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241001489106 Laccaria laccata Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000867233 Prosodes Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- BURBYWNSQNXLSI-UHFFFAOYSA-N gamma-glutamylcystine Natural products OC(=O)C(N)CCC(=O)NC(C(O)=O)CSSCC(N)C(O)=O BURBYWNSQNXLSI-UHFFFAOYSA-N 0.000 description 1
- 108010024953 gamma-glutamylcystine Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.未変性ホエータンパク質濃縮物を、T−ヘルパー細胞濃度およびT−ヘルパ ー細胞/T−サプレッサー細胞の比率を増加させるのに十分な量で投与すること を含んでなる、HIV−血清反応陽性患者の治療法。 2.未変性ホエータンパク質濃縮物の溶解度指数(pH4.6)が99%を上回 るものである、請求の範囲第1項に記載の方法。 3.未変性ホエータンパク質濃縮物が、ベーター−ラクトグロブリン59.1± 4.0、アルファ−ラクトアルブミン6.6±0.7、血清アルブミン9.7± 1.0、免疫グロブリン24.6±2.6を含んでなるタンパク質組成を有する 、請求の範囲第1項に記載の方法。 4.未変性のホエータンパク質濃縮物の量が、一日当たり約8〜40グラムの範 囲である、請求の範囲第1項に記載の方法。 5.前記範囲が一日当たり約20〜40グラムである、請求の範囲第4項に記載 の方法。 6.前記範囲が一日当たり約30〜40グラムである、請求の範囲第5項に記載 の方法。 7.未変性ホエータンパク質濃縮物の血清アルブミン濃度が約10%以上である 、請求の範囲第2項に記載の方法。 8.未変性のホエータンパク質濃縮物が免疫グロブリンを約25〜30%の範囲 で有する、請求の範囲第7項に記載の方法。 9.HIV−血清反応陽性患者の治療における、血中単核細胞のグルタチオン含 量、体重および安堵感を高めるのに十分な量での未変性のホエータンパク質濃縮 物の使用。 10.HIV−血清反応陽性患者の治療における、T−ヘルパー細胞濃度および T−ヘルパー細胞/T−サプレッサー細胞の比率を高めるのに十分な量での未変 性のホエータンパク質濃縮物の使用。 11.未変性のホエータンパク貧濃縮物を含んでなる、HIV−血清反応陽性患 者治療用医薬組成物。 12.未変性のホエータンパク質濃縮物を薬学上許容可能なキャリヤーまたは賦 形剤と共に含んでなる、HIV−血清反応陽性患者治療用医薬組成物。 13.HIV−血清反応陽性患者の治療における医薬としての、血中単核細胞の グルタチオン含量、体重および安堵感を高めるのに十分な量での未変性のホエー タンパク質濃縮物の使用。 14.HIV−血清反応陽性患者の治療におけるT−ヘルパー細胞濃度およびT −ヘルパー細胞/T−サプレッサー細胞の比率を高めるのに十分な量での未変性 のホエータンパク質濃縮物の医薬としての使用。 15.血中単核細胞のグルクチオン含量、体重および安堵感を高めるのに十分な 量での、HIV−血清反応陽性患者治療用医薬を製造するための未変性のホエー タンパク質濃縮物の使用。 16.T−ヘルパー細胞濃度およびT−ヘルパー細胞/T−サプレッサー細胞の 比率を高めるのに十分な量での、HIV−血清反応陽性患者治療用医薬を製造す るための未変性のホエータンパク質濃縮物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US866,756 | 1992-04-10 | ||
US07/866,756 US5456924A (en) | 1988-12-23 | 1992-04-10 | Method of treatment of HIV-seropositive individuals with dietary whey proteins |
PCT/CA1993/000107 WO1993020831A1 (en) | 1992-04-10 | 1993-03-22 | Method of treatment of hiv-seropositive individuals with dietary whey proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07504677A true JPH07504677A (ja) | 1995-05-25 |
JP2738592B2 JP2738592B2 (ja) | 1998-04-08 |
Family
ID=25348339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5517869A Expired - Lifetime JP2738592B2 (ja) | 1992-04-10 | 1993-03-22 | 食餌用ホエータンパク質を用いたhiv‐血清陽性患者の治療法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US5456924A (ja) |
EP (1) | EP0634934B1 (ja) |
JP (1) | JP2738592B2 (ja) |
KR (1) | KR100297959B1 (ja) |
CN (1) | CN1070371C (ja) |
AT (1) | ATE187335T1 (ja) |
AU (1) | AU687731B2 (ja) |
CA (1) | CA2090186C (ja) |
CZ (1) | CZ283386B6 (ja) |
DE (1) | DE69327236T2 (ja) |
DK (1) | DK0634934T3 (ja) |
ES (1) | ES2143503T3 (ja) |
IL (1) | IL105339A (ja) |
MX (1) | MX9302057A (ja) |
NO (1) | NO317795B1 (ja) |
NZ (1) | NZ251271A (ja) |
TW (1) | TW384223B (ja) |
WO (1) | WO1993020831A1 (ja) |
ZA (1) | ZA932526B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017509320A (ja) * | 2014-01-25 | 2017-04-06 | ゲーエーアー テーデーエス ゲーエムベーハー | 乳加工プラントの熱交換器中の好熱性細菌の増殖を減らすための方法および装置 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241983B1 (en) | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
US5985275A (en) * | 1995-04-12 | 1999-11-16 | New York Blood Center | β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection |
CA2165937A1 (en) * | 1995-05-09 | 1996-11-10 | Immunotec Research Corporation Ltd. | Process for producing an undenatured whey protein concentrate |
AU2326297A (en) * | 1996-03-06 | 1997-09-22 | I. Belloch Corporation | Method for treating liquid materials |
US5952009A (en) * | 1996-03-20 | 1999-09-14 | New York Blood Center | Methods for preventing the transmission of or treating patients infected with herpesvirus |
WO1997034619A1 (en) * | 1996-03-20 | 1997-09-25 | New York Blood Center | Methods of treating herpes or chlamydia |
WO1999055326A1 (en) | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
US6667063B2 (en) | 1998-06-10 | 2003-12-23 | Albert Crum | Nutritional or therapeutic supplement and method |
DE69930746T2 (de) * | 1998-06-10 | 2007-03-15 | Crum, Albert B. | Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems |
US6203805B1 (en) | 1998-11-10 | 2001-03-20 | Color Access, Inc. | Topical compositions containing whey proteins |
EP1372641A4 (en) | 2001-03-05 | 2004-08-25 | Stephen P Ernest | ENTERAL FORMULATION |
US6503506B1 (en) * | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
WO2003053158A2 (en) | 2001-12-20 | 2003-07-03 | Technologies Biolactis Inc. | Malleable protein matrix and uses thereof |
FR2840318B1 (fr) * | 2002-05-29 | 2004-12-03 | Quoc Kiet Pham | Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih |
FR2889067B1 (fr) * | 2005-07-29 | 2011-11-11 | Cie Laitiere Europeenne | "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle" |
DE102006052504A1 (de) | 2006-11-06 | 2008-05-08 | Temper, Rupert | Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit |
US20080119386A1 (en) * | 2006-11-22 | 2008-05-22 | Carl Germano | Nutritional formula for athletes' recovery |
AP2009004963A0 (en) * | 2007-02-06 | 2009-10-31 | Cymcorp Internat Inc | Novel non-toxic composition and method of using such for treating a degenerative or an immune systemrelated disease |
US20100069288A1 (en) * | 2008-09-12 | 2010-03-18 | Wulf Droge | Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival |
JP2013079216A (ja) | 2011-10-04 | 2013-05-02 | Snow Brand Milk Products Co Ltd | 感覚改善剤 |
JP6234777B2 (ja) * | 2013-10-31 | 2017-11-22 | 株式会社日立製作所 | 光多値送信器および光トランスポンダ |
CA3038048A1 (en) | 2016-09-23 | 2018-03-29 | Immunotec Inc. | Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders |
CA2970699A1 (en) | 2017-06-14 | 2018-12-14 | Elizabeth E. Ignowski | Compositions for increasing resilience to traumatic brain injury |
US11944649B2 (en) | 2017-07-31 | 2024-04-02 | Immunotec Inc. | Compositions and methods for treatment of autism spectrum disorder |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA858533A (en) * | 1970-12-15 | Lahav Eitan | Polypeptidic antibiotic substances derived from casein by fermentation | |
FR2565985B1 (fr) * | 1984-06-19 | 1987-09-25 | Rhone Poulenc Sante | Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent |
US4880626A (en) * | 1985-01-18 | 1989-11-14 | Mcmichael John | Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome |
US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
US5030449A (en) * | 1988-07-21 | 1991-07-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthetic vaccine against AIDS virus |
DE58904683D1 (de) * | 1988-04-19 | 1993-07-22 | Biotest Pharma Gmbh | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. |
CA1333471C (en) * | 1988-04-29 | 1994-12-13 | Gustavo Bounous | Whey protein concentrate as food supplement |
CA1338682C (en) * | 1988-12-23 | 1996-10-29 | Gustavo Bounous | Biologically active undenatured whey protein concentrate as food supplement |
CA2007258A1 (en) * | 1989-01-11 | 1990-07-11 | Richard L. Jackson | Heparin fraction with anti-hiv activity |
CA2011299A1 (en) * | 1989-03-03 | 1990-09-03 | Franklin Volvovitz | Aids therapy |
ES2095876T3 (es) * | 1989-06-02 | 1997-03-01 | Univ Johns Hopkins Med | Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion |
CA2022394A1 (en) * | 1989-08-07 | 1991-02-08 | Allen I. Oliff | Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins |
ATE366311T1 (de) * | 1989-12-22 | 2007-07-15 | Hoffmann La Roche | Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür |
US5112373A (en) * | 1991-06-17 | 1992-05-12 | Hung Pham | Apparatus for controlling and eliminating vapor emissions at a manicure work station |
-
1992
- 1992-04-10 US US07/866,756 patent/US5456924A/en not_active Expired - Lifetime
-
1993
- 1993-02-23 CA CA002090186A patent/CA2090186C/en not_active Expired - Lifetime
- 1993-03-22 JP JP5517869A patent/JP2738592B2/ja not_active Expired - Lifetime
- 1993-03-22 KR KR1019940703473A patent/KR100297959B1/ko not_active IP Right Cessation
- 1993-03-22 AT AT93907682T patent/ATE187335T1/de active
- 1993-03-22 WO PCT/CA1993/000107 patent/WO1993020831A1/en active IP Right Grant
- 1993-03-22 CZ CZ942461A patent/CZ283386B6/cs not_active IP Right Cessation
- 1993-03-22 AU AU38812/93A patent/AU687731B2/en not_active Expired
- 1993-03-22 EP EP93907682A patent/EP0634934B1/en not_active Expired - Lifetime
- 1993-03-22 DE DE69327236T patent/DE69327236T2/de not_active Expired - Lifetime
- 1993-03-22 NZ NZ251271A patent/NZ251271A/en unknown
- 1993-03-22 ES ES93907682T patent/ES2143503T3/es not_active Expired - Lifetime
- 1993-03-22 DK DK93907682T patent/DK0634934T3/da active
- 1993-04-07 MX MX9302057A patent/MX9302057A/es unknown
- 1993-04-08 IL IL10533993A patent/IL105339A/en not_active IP Right Cessation
- 1993-04-08 ZA ZA932526A patent/ZA932526B/xx unknown
- 1993-04-09 CN CN93104081A patent/CN1070371C/zh not_active Expired - Lifetime
- 1993-04-09 TW TW082102661A patent/TW384223B/zh not_active IP Right Cessation
-
1994
- 1994-10-07 NO NO19943804A patent/NO317795B1/no not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017509320A (ja) * | 2014-01-25 | 2017-04-06 | ゲーエーアー テーデーエス ゲーエムベーハー | 乳加工プラントの熱交換器中の好熱性細菌の増殖を減らすための方法および装置 |
Also Published As
Publication number | Publication date |
---|---|
KR100297959B1 (ko) | 2001-10-24 |
US5456924A (en) | 1995-10-10 |
NO317795B1 (no) | 2004-12-13 |
ZA932526B (en) | 1994-03-09 |
CN1083704A (zh) | 1994-03-16 |
KR950700752A (ko) | 1995-02-20 |
AU3881293A (en) | 1993-11-18 |
CZ246194A3 (en) | 1995-04-12 |
WO1993020831A1 (en) | 1993-10-28 |
NO943804D0 (no) | 1994-10-07 |
AU687731B2 (en) | 1998-03-05 |
DK0634934T3 (da) | 2000-06-13 |
MX9302057A (es) | 1994-07-29 |
TW384223B (en) | 2000-03-11 |
EP0634934B1 (en) | 1999-12-08 |
IL105339A (en) | 1998-07-15 |
CZ283386B6 (cs) | 1998-04-15 |
DE69327236T2 (de) | 2000-03-30 |
CN1070371C (zh) | 2001-09-05 |
CA2090186A1 (en) | 1993-10-11 |
ATE187335T1 (de) | 1999-12-15 |
NZ251271A (en) | 1998-05-27 |
IL105339A0 (en) | 1993-08-18 |
NO943804L (no) | 1994-10-07 |
EP0634934A1 (en) | 1995-01-25 |
DE69327236D1 (de) | 2000-01-13 |
CA2090186C (en) | 1999-03-16 |
ES2143503T3 (es) | 2000-05-16 |
JP2738592B2 (ja) | 1998-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07504677A (ja) | 食餌用ホエータンパク質を用いたhiv‐血清陽性患者の治療法 | |
Baruchel et al. | Whey proteins as a food supplement in HIV-seropositive individuals | |
CA1338682C (en) | Biologically active undenatured whey protein concentrate as food supplement | |
Yalcin | Emerging therapeutic potential of whey proteins and peptides | |
US5451412A (en) | Biologically active undenatured whey protein concentrate as food supplement | |
EP1858355A1 (en) | High pressure processing of metal ion lactoferrin | |
Kassem | Future challenges of whey proteins | |
JP2008115194A (ja) | 癌の予防または治療用医薬組成物 | |
US5888552A (en) | Anti-cancer therapeutic compositions containing whey protein concentrate | |
Gupta et al. | Whey proteins and its impact on human health nutrition: review | |
Elkot | Characterization and healthier properties of whey proteins of camel milk: A review | |
Gougerot-Pocidalo | Bounous et al. | |
Bounous et al. | Whey proteins as a food supplement in EŒV-seropositive individuals | |
Matcoff | Influence of Protein Nutrition on Experimental Infection—Physiological Aspects | |
Bounous | 54). ANTI-CANCER THERAPEUTIC | |
Alghamdi | THE FUNCTIONAL CHARACTERISTICS OF THE VITAL ACTIVE COMPOUNDS VITAL IN CAMEL MILK AND ITS ROLE IN HEALTH PROMOTION | |
Khan | Received: 19 th Jan-2013 Revised: 31 st Jan-2013 Accepted: 2 nd Feb-2013 Research article WHEY PROTEIN HYDROLYSATES: TECHNO-FUNCTIONAL PERSPECTIVE | |
Drew | The provision of passive immunity to colostrum-deprived piglets by bovine or porcine serum immunoglobulins, iron chelators and viable leukocytes | |
Mercuriali et al. | Albumin: Is It a Play-Maker, a Carrier or Both? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090116 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090116 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100116 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110116 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110116 Year of fee payment: 13 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110116 Year of fee payment: 13 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110116 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120116 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130116 Year of fee payment: 15 |